Literature DB >> 160469

Effects of 2-nicotinamidoethyl nitrate on the cardiovascular system.

Y Nakagawa, K Takeda, Y Katano, T Tsukada, T Kitagawa, T Otorii, S Imai.   

Abstract

Using the dog as experimental animal, effects on the cardiovascular system of a new vasodilator, 2-nicotinamidoethyl nitrate (SG-75), were studied. In the heart-lung preparation, the compound produced a dose-dependent increase in the coronary blood flow, which was associated with only a minimal increase in the myocardial oxygen consumption. There was essentially no change in the myocardial function. The myocardial redox potential was shifted to more positive values. In the isolated perfused heart preparation (Langendorff's preparation), SG-75 produced a dilatation of only the small resistive arterioles. However, it produced a dilatation of the large conductive artery in underperfused myocardium. SG-75 produced a significant increase in the cerebral venous outflow, associated with an increase in the cerebro-spinal fluid pressure. It produced a reducation of the venous return, which was especially prominent in the lower half of the body. In the isolated smooth muscle preparation of the coronary artery, high-doses of SG-75 induced calcium antagonistic effects and produced a relaxation of the lanthanum contracture.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 160469     DOI: 10.1536/ihj.20.881

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  8 in total

Review 1.  Pharmacology and therapeutic effects of nicorandil.

Authors:  M Kinoshita; K Sakai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Left ventricular effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.

Authors:  K Hashimoto; Y Ohbayashi; M Kinoshita
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

3.  Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility.

Authors:  A Baumbach; U Braun; G Döring; K K Haase; W Voelker; K R Karsch
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

4.  Study of the efficacy of nicorandil in patients with ischaemic heart disease using Exercise-T1-201 myocardial tomography.

Authors:  J Yamazaki; H Ohsawa; T Uchi; M Iida; H Nakano; H Hosoi; T Morishita; Y Yabe; N Koyama; H Komatsu
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.

Authors:  S Di Somma; V Liguori; M Petitto; A Carotenuto; D Bokor; O de Divitiis; M de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

6.  Protection by nicorandil against the dysfunction of the central vagal baroreflex system following transient global cerebral ischaemia in dogs.

Authors:  J Kurihara; N Ochiai; H Kato
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  Effectiveness of nicorandil in the preservation of myocardium stressed by transient ischemia and its influence on cardiac metabolism during coronary artery occlusion with subsequent reperfusion: a comparison with isosorbide dinitrate.

Authors:  H Korb; A Hoeft; D H Hunneman; R Schraeder; H G Wolpers; G Hellige
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

8.  Vasodilating effects of nicorandil and nitroglycerin in anaesthetized open-chest dogs.

Authors:  M Sakanashi; K Noguchi; T Kato; R Sunagawa; H Ito; J Nakasone
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.